Edinburgh Research Explorer

Antigen-based immunotherapy (AIT) for autoimmune and allergic disease

Research output: Contribution to journalLiterature review

Related Edinburgh Organisations

Open Access permissions



  • Download as Adobe PDF

    Rights statement: Under a Creative Commons license - CC-BY

    Final published version, 486 KB, PDF document

    Licence: Creative Commons: Attribution (CC-BY)

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalCurrent Opinion in Pharmacology
Early online date22 May 2015
Publication statusPublished - Aug 2015


Autoimmune and allergic diseases are major causes of morbidity. Antigen-based immunotherapy (AIT) is immunologically the most satisfying means of specifically targeting only those T cells driving disease, thereby inducing antigen-specific immune tolerance, with the lowest adverse risk profile. AIT is highly effective in rodent models of T cell-driven inflammation and is now in clinical trials. The range of approaches to applying AIT in the clinic prevents a consensus on the molecular basis for this form of tolerance. In particular, there has been a paucity of information on how pre-activated effector and memory T cells respond to AIT. New, advanced murine models of AIT are beginning to deliver such information at the cellular, biochemical, transcriptional and epigenetic levels.

Download statistics

No data available

ID: 19849650